Latest Commercialization News

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

EVE Health Group has completed manufacturing and distribution setup for Libbo™, its innovative oral dissolving film for erectile dysfunction, paving the way for near-term patient access via telehealth and pharmacy channels.

FlexiRoam has reported its second consecutive quarter of positive operating cash flow and returned to a positive net current asset position for the first time in over eight years, underpinned by record underlying EBITDA and strategic AI partnerships.

Janus Electric reports operational progress with validated technology and increased revenue, while focusing on commercial execution and cost discipline under new CEO Ben Hutt. Funding remains a critical factor for sustaining growth.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

One Click Group Limited has reported a robust 28% increase in revenue for 2025 alongside a significant expansion in its user base and the rollout of an upgraded cash advance product. The fintech’s strategic focus on growth and innovation sets the stage for a promising 2026.

Nanollose has advanced its largest pilot production of Nullarbor™ fibre, integrating a refined microbial cellulose process that promises easier adoption by textile manufacturers. The company also bolstered its intellectual property portfolio and secured additional funding post-quarter.

Harvest Technology Group reports improved first-half FY26 financials alongside strategic defense sector expansions, including new reseller agreements and NATO engagements.

Dotz Nano has achieved a key production milestone for its proprietary CO2 sorbent materials and raised over AU$3 million to accelerate commercialization of its DotzEarth technology.

Anatara Lifesciences reports encouraging interim pre-clinical results for its Anti-Obesity Project, with a candidate compound showing significant effects on weight regain and visceral fat in mice. The company also completed a $1.2 million capital raise, bolstering its financial position as it advances research.